China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen. The deal grants Chipscreen exclusive development, manufacturing, and commercialization rights to Eucure’s bispecific antibody (BsAb) YH008 in Greater China, including Hong Kong, Macau, and Taiwan.
Financial Terms of the Agreement
Under the terms of the agreement, Chipscreen NewWay will pay Eucure Biopharma an upfront payment of RMB 40 million (USD 5.76 million), a potential development milestone payment of up to RMB 360 million (USD 51.87 million), and a potential sales milestone payment of up to RMB 196 million (USD 28.24 million). Additionally, Chipscreen will pay tiered royalties on net sales.
YH008: First-in-Class Bispecific Antibody
YH008 is a potential first-in-class tetravalent anti PD-1/CD40 Fc-silenced IgG1 bispecific antibody (BsAb) that agonizes CD40 in a PD-1-dependent manner. This innovative drug is currently in the preclinical stages of development, positioning it as a promising candidate in the field of immuno-oncology.
Strategic Implications
The licensing agreement between Chipscreen Biosciences and Eucure Biopharma represents a strategic move to enhance Chipscreen’s pipeline with a potentially groundbreaking therapy. By securing the rights to YH008, Chipscreen is poised to expand its presence in the Greater China market and contribute to the development of novel treatments for cancer. This partnership leverages the strengths of both companies, combining Eucure’s research capabilities with Chipscreen’s development and commercial expertise.-Fineline Info & Tech
